NEW YORK (TheStreet) -- Shares of NantKwest Inc  (NK) - Get Report were surging to trade at $36.49 in afternoon trading Tuesday, as the clinical-stage immunotherapy company makes its initial public offering debut on the Nasdaq.

The company priced its IPO of 8.288 million shares of its common stock at a price to the public of $25 a piece, raising $207 million.

Initially the company planned to offer 7 million shares at a price range of between $20 to $23 a share.

NantKwest has granted the underwriters a 30-day option to buy an additional 1,243,200 shares of its common stock.

In addition, NantKwest is selling 680,000 shares of its common stock in a separate private placement to Celgene Corp (CELG) - Get Report, an existing stockholder, at $25 per share.

BofA Merrill Lynch (BAC) - Get Report, Citigroup Global Markets (C) - Get Report, Jefferies (JEF) - Get Report and Piper Jaffray (PJC) - Get Report are acting as joint book-running managers for the offering.

Calif.-based NantKwest, formerly Conkwest, is a clinical-stage immunotherapy company focused on using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.

NK Price data by YCharts

Image placeholder title